These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27552578)

  • 1. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry.
    Oh S; Goto S; Accetta G; Angchaisuksiri P; Camm AJ; Cools F; Haas S; Kayani G; Koretsune Y; Lim TW; Misselwitz F; van Eickels M; Kakkar AK;
    Int J Cardiol; 2016 Nov; 223():543-547. PubMed ID: 27552578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
    Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
    PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
    Sawhney JP; Kothiwale VA; Bisne V; Durgaprasad R; Jadhav P; Chopda M; Vanajakshamma V; Meena R; Vijayaraghavan G; Chawla K; Allu J; Pieper KS; John Camm A; Kakkar AK;
    Indian Heart J; 2018; 70(6):828-835. PubMed ID: 30580852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
    Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
    BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).
    Fox KAA; Accetta G; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Kayani G; Kakkar AK;
    Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):27-35. PubMed ID: 28950344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
    Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.
    Apenteng PN; Gao H; Hobbs FR; Fitzmaurice DA;
    BMJ Open; 2018 Jan; 8(1):e018905. PubMed ID: 29331969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.
    Haas S; Camm JA; Harald D; Steffel J; Virdone S; Pieper K; Brodmann M; Schellong S; Misselwitz F; Kayani G; Kakkar AK;
    Clin Res Cardiol; 2023 Jun; 112(6):759-771. PubMed ID: 36094573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.
    Goto S; Angchaisuksiri P; Bassand JP; Camm AJ; Dominguez H; Illingworth L; Gibbs H; Goldhaber SZ; Goto S; Jing ZC; Haas S; Kayani G; Koretsune Y; Lim TW; Oh S; Sawhney JPS; Turpie AGG; van Eickels M; Verheugt FWA; Kakkar AK;
    J Am Heart Assoc; 2019 Feb; 8(3):e010510. PubMed ID: 30717616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry.
    Stępińska J; Kremis E; Konopka A; Wożakowska-Kapłon B; Ruszkowski P; Kukla P; Kayani G
    Kardiol Pol; 2016; 74(4):362-71. PubMed ID: 26365937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.
    Goto S; Goto S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Haas S; Parkhomenko A; Oto A; Misselwitz F; Turpie AGG; Verheugt FWA; Fox KAA; Gersh BJ; Kakkar AK
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):301-309. PubMed ID: 31821482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.
    Fitzmaurice DA; Accetta G; Haas S; Kayani G; Lucas Luciardi H; Misselwitz F; Pieper K; Ten Cate H; Turpie AG; Kakkar AK;
    Br J Haematol; 2016 Aug; 174(4):610-23. PubMed ID: 27071942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
    Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Features, management and prognosis of Chilean patients with non valvular atrial fibrillation: GARFIELD AF registry].
    Corbalán R; Conejeros C; Rey C; Stockins B; Eggers G; Astudillo C; Lanas F; Potthoff S; Houzvic C; Montecinos H; Charme G; Bugueño C; Aguilar J; Arriagada G; Marín P; Larico M
    Rev Med Chil; 2017 Aug; 145(8):963-971. PubMed ID: 29189853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
    Steinberg BA; Gao H; Shrader P; Pieper K; Thomas L; Camm AJ; Ezekowitz MD; Fonarow GC; Gersh BJ; Goldhaber S; Haas S; Hacke W; Kowey PR; Ansell J; Mahaffey KW; Naccarelli G; Reiffel JA; Turpie A; Verheugt F; Piccini JP; Kakkar A; Peterson ED; Fox KAA; ;
    Am Heart J; 2017 Dec; 194():132-140. PubMed ID: 29223431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.